Peptide-Based Therapeutics in Human Male Fertility: Molecular Mechanisms, Translational Evidence, and Clinical Prospects

Abstract

Male infertility accounts for approximately 40–50% of infertility cases globally and represents a growing public health challenge associated with declining sperm quality, endocrine dysfunction, and environmental stressors. Conventional treatments, including hormonal therapy, antioxidant supplementation, and assisted reproductive technologies, often address symptoms rather than the underlying molecular pathology responsible for impaired spermatogenesis. Peptide-based therapeutics have recently emerged as promising biologic regulators capable of restoring reproductive homeostasis at the molecular level. Bioactive peptides, short amino-acid sequences acting as regulatory signalling molecules, modulate critical pathways governing endocrine regulation, mitochondrial bioenergetics, oxidative stress control, angiogenesis, and tissue regeneration. Evidence from mammalian translational models demonstrates that peptide therapies enhance spermatogenic activity, improve sperm motility and mitochondrial function, restore steroidogenic signalling, and promote gonadal tissue repair. Particularly promising are mitochondrial-targeted peptides and organ-specific peptide complexes that regulate steroidogenesis via pathways involving StAR, PGC-1α, NRF1, and TFAM. Emerging nano-delivery technologies further enhance peptide stability, tissue targeting, and bioavailability. Integration of peptide therapeutics with precision medicine approaches may enable individualized fertility restoration strategies. This review synthesizes current mechanistic, experimental, and translational evidence supporting peptide therapeutics as a next-generation modality in human male reproductive medicine.

Keywords:male infertility, peptide therapeutics, mitochondrial peptides, spermatogenesis, oxidative stress, HPG axis, reproductive biotechnology

Introduction

Male reproductive health represents a critical determinant of human fertility, population sustainability, and long-term demographic stability [1,2]. Infertility affects approximately 10–15% of couples globally, and male factors are implicated in nearly half of these cases, either as a sole cause or in combination with female reproductive disorders [3]. Recent epidemiologic analyses suggest that the burden of male infertility is increasing worldwide, reflecting both improved diagnostic recognition and a growing prevalence of underlying biological risk factors. In parallel, large-scale meta- analyses have documented a substantial decline in sperm concentration and total sperm counts over the past several decades. Levine and colleagues reported that sperm counts among men from Western countries decreased by more than 50% between 1973 and 2011, a trend that has continued into the present decade [2]. These observations have generated considerable concern within the reproductive health community, raising questions regarding the environmental, metabolic, and molecular determinants of declining male fertility.

Male infertility encompasses a heterogeneous spectrum of clinical conditions that impair the production, maturation, or function of spermatozoa. These disorders are conventionally categorized according to abnormalities in semen parameters, including oligospermia (reduced sperm concentration), azoospermia (complete absence of sperm), asthenozoospermia (reduced sperm motility), teratozoospermia (abnormal sperm morphology), and endocrine-related infertility associated with hormonal dysregulation [4]. Although these phenotypic categories are widely used in clinical andrological practice, they represent downstream manifestations of complex underlying biological processes [5]. Increasing evidence indicates that male infertility frequently results from the interplay of endocrine disturbances, oxidative stress, mitochondrial dysfunction, inflammatory signalling, genetic abnormalities, and environmental exposures [6]. Understanding how these mechanisms converge to disrupt spermatogenesis and sperm function remains an area of active investigation.

At the physiological level, male reproductive function is governed by the tightly regulated Hypothalamic–Pituitary–Gonadal (HPG) axis, which coordinates endocrine signaling required for spermatogenesis and androgen production [6]. Pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus stimulates the pituitary to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). LH acts primarily on Leydig cells to stimulate testosterone synthesis, whereas FSH regulates Sertoli cell function and supports germ-cell maturation within the seminiferous tubules [7]. Disruption of this regulatory network can impair testosterone production, compromise Sertoli cell support of developing germ cells, and ultimately lead to defective spermatogenesis [7]. Endocrine abnormalities such as hypogonadotropic hypogonadism, altered feedback regulation of gonadotropins, or disturbances in androgen signaling therefore represent important contributors to male reproductive dysfunction [8]. Beyond endocrine regulation, emerging evidence highlights the central role of cellular metabolism and mitochondrial function in determining sperm quality and fertilization capacity. Mitochondria located in the sperm midpiece generate Adenosine Triphosphate (ATP) required for flagellar movement and progressive motility [9]. Impairment of mitochondrial oxidative phosphorylation can therefore directly compromise sperm motility and fertilization competence [10]. Moreover, mitochondria serve as a major source of Reactive Oxygen Species (ROS), which at physiological levels participate in essential processes such as sperm capacitation and acrosome reaction but become deleterious when produced in excess [9]. Elevated oxidative stress within the male reproductive tract can induce lipid peroxidation of sperm membranes, DNA fragmentation, and apoptosis of germ cells [11]. Indeed, oxidative stress is now recognized as one of the most prevalent molecular contributors to male infertility, implicated in up to 80% of idiopathic infertility cases [12]. Environmental and lifestyle factors further amplify these biological vulnerabilities. Exposure to endocrine-disrupting chemicals, heavy metals, air pollutants, and agricultural pesticides has been associated with impaired semen quality and reduced reproductive potential [13]. Similarly, metabolic disorders such as obesity, diabetes mellitus, and metabolic syndrome have been linked to altered hormonal signalling, increased oxidative stress, and disruption of testicular function [14]. These multifactorial influences suggest that male infertility should be understood not as a single disease entity but rather as a complex systems-level disorder arising from the intersection of endocrine, metabolic, environmental, and genetic determinants. This systems-level perspective reframes male infertility as a failure of coordinated biological networks rather than isolated dysfunction within a single pathway. Disruptions in endocrine signaling, mitochondrial bioenergetics, redox homeostasis, and immune regulation do not occur independently but instead interact dynamically to destabilize the testicular microenvironment required for spermatogenesis. Consequently, therapeutic strategies that target only downstream manifestations may be insufficient to restore physiological reproductive function. In this context, bioactive peptides have emerged as candidate modulators of these interconnected systems, functioning not as conventional supplements but as signaling molecules capable of interfacing with endogenous regulatory pathways. By influencing receptor-mediated signaling, transcriptional networks, and cellular stress responses, peptide-based interventions offer a mechanistically integrated approach to restoring reproductive homeostasis at the molecular level (Table 1).

Table 1:Causes of Male Infertility.

Despite advances in diagnostic evaluation, therapeutic options for male infertility remain limited. Current management strategies primarily focus on correcting endocrine abnormalities or circumventing impaired sperm function through Assisted Reproductive Technologies (ART), including In Vitro Fertilization (IVF) and intracytoplasmic sperm injection [15]. Although these approaches have improved reproductive outcomes for many couples, they often bypass rather than correct the underlying biological processes responsible for impaired fertility [16]. Moreover, ART procedures are associated with substantial financial cost, psychological burden, and potential health risks, highlighting the need for alternative therapeutic strategies that directly target the molecular drivers of male reproductive dysfunction [17].

In recent years, advances in molecular biology, regenerative medicine, and peptide biotechnology have stimulated growing interest in bioactive peptides as modulators of reproductive physiology. Peptides are short amino-acid chains that function as signaling molecules capable of regulating cellular metabolism, gene expression, immune responses, and endocrine pathways [18]. Unlike traditional pharmacologic agents that broadly affect systemic physiology, peptides often exhibit high receptor specificity and act through physiologic signaling networks, enabling more targeted modulation of biological processes [19]. In the context of reproductive biology, peptide-mediated signaling has been implicated in diverse processes including steroidogenesis, mitochondrial regulation, angiogenesis, and cellular stress responses [20].

Particularly intriguing are mitochondrial-derived peptides and organ-specific regulatory peptides, which have been shown to influence cellular energy metabolism, oxidative balance, and tissue regeneration. Experimental studies suggest that such peptides can enhance mitochondrial biogenesis, reduce oxidative damage, and modulate transcriptional pathways involved in cellular resilience [21,22]. These mechanisms are highly relevant to male reproductive function, as spermatogenesis and sperm motility are energetically demanding processes that depend on efficient mitochondrial metabolism and tightly regulated redox homeostasis. Moreover, peptide signaling pathways may influence endocrine regulation within the HPG axis and support the maintenance of the testicular microenvironment necessary for germ-cell development [23].

The integration of peptide therapeutics into reproductive medicine therefore represents a promising avenue for addressing the molecular drivers of male infertility. By targeting pathways involved in cellular energy metabolism, oxidative stress regulation, and endocrine signaling, peptides have the potential to restore physiological homeostasis within the male reproductive system rather than merely compensating for downstream functional deficits. Although clinical data remain limited, accumulating evidence from translational and experimental studies supports the concept that peptide-based interventions may enhance spermatogenic activity, improve sperm quality, and promote reproductive tissue repair. Given the growing prevalence of male infertility and the limitations of current therapeutic approaches, there is a pressing need to better understand the molecular mechanisms underlying reproductive dysfunction and to explore innovative treatment strategies capable of restoring reproductive health.

Pathophysiology of Male Infertility

Disruption of GnRH pulsatility alters the temporal dynamics of pituitary gonadotropin secretion, leading to impaired Leydig cell steroidogenesis and compromised Sertoli cell support of germ-cell development. upstream regulatory pathways play a critical role in maintaining GnRH neuronal activity. Kisspeptin-expressing neurons within the hypothalamus act as central modulators of GnRH release, integrating metabolic and hormonal signals to coordinate reproductive function [24]. Perturbations in kisspeptin signaling have been directly associated with hypogonadotropic states and reduced gonadotropin output. In parallel, systemic metabolic cues, e.g., leptin and insulin, modulate hypothalamic function, linking energy homeostasis to reproductive capacity. Dysregulation of these pathways, particularly in obesity and metabolic syndrome, can suppress GnRH secretion and downstream androgen production [25].

Hypothalamic–Pituitary–Gonadal Axis Dysfunction

At the peripheral level, circulating Sex Hormone–Binding Globulin (SHBG) critically determines the fraction of bioavailable testosterone accessible to target tissues [24]. Age-related increases in SHBG contribute to a progressive decline in free testosterone despite relatively stable total testosterone concentrations. Longitudinal studies indicate that total testosterone levels decline by approximately 1–2% annually in aging males, with a more pronounced reduction in bioavailable androgen due to rising SHBG concentrations [26]. This endocrine shift has significant implications for spermatogenesis, as intratesticular testosterone concentrations are essential for maintaining germ-cell maturation. Collectively, these findings highlight that HPG axis dysfunction extends beyond hormonal deficiency to encompass disruptions in neuroendocrine regulation, metabolic signaling, and hormone bioavailability [27]. Such disturbances may arise from congenital hypogonadotropic hypogonadism, metabolic disorders, systemic illness, or environmental endocrine disruptors that interfere with steroidogenic signaling pathways [8]. In addition to classical reproductive hormones, emerging biomarkers such as Anti-Müllerian Hormone (AMH) and insulin-like peptide 3 (INSL3) provide important insights into Sertoli and Leydig cell function, respectively [28]. Altered concentrations of these biomarkers reflect disturbances within the testicular microenvironment and have been associated with impaired spermatogenic capacity and reduced semen quality [29] (Table 2).

Alterations in AMH, INSL3, and testosterone levels are therefore increasingly recognized as clinically relevant biomarkers of testicular dysfunction and endocrine dysregulation in infertile men [30,31].

Table 2:Key Hormones Involved in the HPG Axis

Oxidative Stress

Excessive Reactive Oxygen Species (ROS) production disrupts redox homeostasis and induces lipid peroxidation of sperm membranes, compromising membrane fluidity and functional integrity [32]. his process is accompanied by the accumulation of oxidative biomarkers, including 8-hydroxy-2′-deoxyguanosine (8-OHdG), which reflects oxidative DNA damage, and Malondialdehyde (MDA), a byproduct of lipid peroxidation. Concurrent depletion of intracellular antioxidant systems, particularly reduced glutathione, further exacerbates cellular vulnerability to oxidative injury [11,33]. These molecular alterations impair sperm motility, disrupt chromatin integrity, and reduce fertilization potential [11]. The sperm plasma membrane contains exceptionally high concentrations of polyunsaturated fatty acids that are highly susceptible to lipid peroxidation [34]. In addition, mature sperm cells possess minimal cytoplasmic antioxidant defenses due to the extensive cytoplasmic reduction that occurs during spermiogenesis [35]. Importantly, oxidative stress does not act in isolation but is closely coupled to mitochondrial dysfunction. Excess ROS generated during oxidative phosphorylation can damage mitochondrial membranes and mitochondrial DNA, initiating a self-perpetuating cycle of oxidative injury. This interplay between ROS generation and mitochondrial impairment represents a central mechanism linking environmental stressors, metabolic dysfunction, and declining sperm quality [33].

Mitochondrial Dysfunction

Sperm function is critically dependent on mitochondrial oxidative phosphorylation, which is mediated by electron transport chain complexes I–V embedded within the inner mitochondrial membrane [36]. Emerging evidence indicates that mitochondrial dysfunction in male infertility is characterized by a bidirectional feedback loop in which ROS-induced mitochondrial damage further enhances ROS generation, amplifying cellular injury. This cycle contributes to progressive declines in sperm motility and viability. In addition, mitochondrial dysfunction has been linked to broader hallmarks of cellular aging, including telomere shortening and replicative senescence, which may further impair germ-cell renewal capacity [37].

Inflammation and Immune Dysregulation

Chronic inflammatory signaling within the male reproductive tract disrupts the specialized microenvironment required for spermatogenesis. Activation of nuclear factor kappa B (NF-κB) pathways in response to infection, metabolic stress, or tissue injury leads to increased production of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. These cytokines not only induce germ-cell apoptosis but also interfere with Sertoli cell function and disrupt intercellular communication within the seminiferous epithelium [38,39]. Inflammatory signaling also exerts direct effects on mitochondrial function, as cytokine-mediated pathways can impair electron transport chain activity and increase mitochondrial ROS production. This interaction further reinforces the link between inflammation and oxidative stress in male infertility.

In addition, disruption of the blood–testis barrier compromises immune privilege within the testes, exposing germ-cell antigens to the systemic immune system and promoting the formation of antisperm antibodies. Such immune-mediated responses can impair sperm function and reduce fertilization capacity, highlighting the importance of immune homeostasis in maintaining reproductive health. These interconnected mechanisms illustrate the multifactorial nature of male infertility and highlight the importance of therapeutic strategies capable of restoring physiological homeostasis across multiple biological systems. Understanding these pathogenic pathways provides a mechanistic foundation for exploring novel molecular interventions aimed at improving male reproductive health.

Table 3 highlights molecular pathways implicated in the pathophysiology of male infertility, integrating endocrine, metabolic, oxidative, mitochondrial, and inflammatory mechanisms. Disruptions within the HPG axis alter gonadotropin signaling and androgen bioavailability, while oxidative stress and mitochondrial dysfunction converge to impair sperm bioenergetics and genomic integrity. Inflammatory signaling further exacerbates these effects through cytokine-mediated damage and breakdown of immune privilege within the testes. The interconnected nature of these pathways highlights the systems-level basis of male infertility and underscores the need for therapeutic strategies capable of targeting multiple biological domains simultaneously. These integrated mechanisms provide a conceptual framework for the targeted application of peptide-based therapeutics discussed in subsequent sections (Table 3).

Table 3:Molecular Pathways Implicated in the Pathophysiology of Male Infertility.

Biological Basis of Peptide Therapeutics

Peptides function as endogenous signaling molecules that regulate cellular physiology through highly specific molecular interactions. Their biological activity is mediated through diverse signaling modalities, including activation of G-Protein–Coupled Receptors (GPCRs), such as melanocortin and neuropeptide receptors, engagement of receptor tyrosine kinases, and direct intracellular interactions with transcriptional regulators [40]. Through these mechanisms, peptides influence key cellular processes including metabolic regulation, stress-response signaling, and gene expression networks that govern cellular adaptation and survival [41]. Unlike conventional pharmacologic agents that often act through broad systemic effects, peptides typically operate within physiological signaling cascades, allowing targeted modulation of discrete molecular pathways. In reproductive biology, such signaling is particularly relevant given the need for precise coordination between endocrine, metabolic, and cellular processes. Peptide-mediated regulation of intracellular signaling pathways enables modulation of transcription factors, mitochondrial function, and inflammatory responses that collectively shape the testicular microenvironment [42]. However, the therapeutic application of peptides is constrained by inherent pharmacokinetic limitations. Native peptides are highly susceptible to proteolytic degradation, resulting in short biological half-lives and reduced systemic stability. Rapid enzymatic breakdown within plasma and tissues limits their bioavailability and necessitates the development of specialized delivery systems to preserve biological activity [43]. Advances in peptide stabilization, including chemical modification, encapsulation within nanocarriers, and sustained-release formulations, have therefore become critical for enabling effective clinical translation. These strategies not only enhance peptide stability but also facilitate targeted delivery to specific tissues, improving therapeutic precision while minimizing off-target effects [44]. Because peptides are derived from naturally occurring amino-acid sequences, they generally demonstrate high receptor specificity and reduced off-target effects [44]. Their structural similarity to endogenous signaling molecules also contributes to favourable safety profiles, including relatively low systemic toxicity and minimal immunogenicity when compared with larger protein therapeutics [45]. Furthermore, peptides can often be designed to mimic physiological signaling pathways rather than disrupt them, allowing targeted modulation of biological processes that are dysregulated in disease states [46]. Spermatogenesis is a highly energy-dependent and tightly regulated developmental process that requires coordinated endocrine signaling, efficient mitochondrial metabolism, adequate vascular supply, and protection from oxidative and inflammatory stress [47].

Endocrine Modulation

Through influencing neuroendocrine signaling by modulating the release of GnRH from hypothalamic neurons or altering the sensitivity of pituitary gonadotroph cells to GnRH stimulation, peptide- mediated signaling can enhance the secretion of LH and follicle- stimulating hormone, the two principal pituitary hormones responsible for regulating testicular function [23]. By influencing these hormonal pathways, peptides may help restore endocrine balance in individuals with functional disruptions of the HPG axis, [48] particularly relevant in conditions characterized by impaired gonadotropin secretion, age-related hormonal decline, or metabolic disorders that interfere with androgen signaling. Importantly, peptide-mediated endocrine modulation differs from conventional hormone replacement strategies because it acts upstream within physiological signaling pathways, potentially allowing restoration of endogenous hormone production rather than reliance on exogenous hormone supplementation [49].

Mitochondrial Bioenergetic Restoration

Mitochondria are central to sperm physiology because they generate the ATP required for flagellar movement and progressive motility [50]. Dysfunctional mitochondria reduce ATP availability and can impair sperm motility, viability, and fertilization potential [36,51]. Certain bioactive peptides, including mitochondrial-derived peptides, have been shown to influence mitochondrial metabolism by stabilizing mitochondrial membrane potential, improving electron transport chain efficiency, and reducing the accumulation of ROS generated during oxidative phosphorylation [41]. These effects help maintain cellular redox balance and prevent oxidative damage to mitochondrial DNA and membrane structures [11]. Peptides have also been shown to activate transcriptional pathways involved in mitochondrial biogenesis and metabolic adaptation [52]. Key regulatory proteins such as peroxisome proliferator–activated receptor gamma coactivator 1-alpha (PGC-1α), Nuclear Respiratory Factor 1 (NRF1), and mitochondrial Transcription Factor A (TFAM) coordinate the replication of mitochondrial DNA and the synthesis of mitochondrial proteins required for oxidative phosphorylation [53]. Activation of these pathways can enhance mitochondrial density and metabolic capacity within cells. In germ cells and spermatozoa, improved mitochondrial bioenergetics may translate into enhanced sperm motility, improved resistance to oxidative stress, and greater overall reproductive competence [50].

Angiogenesis and Microvascular Support

Adequate vascularization is essential for maintaining the metabolic and endocrine functions of reproductive tissues [54]. The testes possess an extensive microvascular network that supplies oxygen, nutrients, and hormonal signals required for germ-cell development and steroidogenesis. Impairment of testicular blood flow has been associated with reduced spermatogenic activity and compromised testosterone production [55]. Peptide signaling pathways can influence angiogenesis by modulating the activity of VEGF and other angiogenic mediators that regulate endothelial- cell proliferation and capillary formation [56]. Enhanced angiogenic signaling promotes the formation of new blood vessels and improves tissue perfusion within reproductive organs. Improved microvascular circulation may facilitate more efficient nutrient delivery, waste removal, and endocrine communication within the testicular microenvironment [57]. In this way, peptides that stimulate angiogenic pathways may indirectly support spermatogenesis by optimizing the metabolic and hormonal conditions required for germ-cell development.

Paracrine Regeneration and Secretome Signaling